CX614 

CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression^[1][2].

CX614 (100 μM) promotes glutamate apparent affinity and increases glutamate-evoked inward currents, increasing the peak glutamate response at 3.5 and 10 mM in HEK293 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CX614 (1 or 10 mg/kg, i.p., twice a day) significantly increases BDNF mRNA in hippocampus and cortex of P5 mice, confirming upregulation of hippocampal BDNF mRNA levels by positive allosteric modulators of AMPA receptors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

247.25

C₁₃H₁₃NO₄

191744-13-5

Solid

Off-white to light brown

O=C1C2=CC3=C(C=C2OC4N1CCC4)OCCO3

Room temperature in continental US; may vary elsewhere.

• [1]. Wei Dai, et al. The Impact and Mechanism of a Novel Allosteric AMPA Receptor Modulator LCX001 on Protection Against Respiratory Depression in Rodents. Front Pharmacol. 2019 Feb 19;10:105.  [Content Brief]

  [2]. Eleni Dicou, et al. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res. 2003 Apr 25;970(1-2):221-5.  [Content Brief]